IMARC Group, a leading market research company, has recently released a report titled “Drug-Eluting Stents Market Report by Coating (Polymer Based Coating, Polymer Free Coating), Drug (Sirolimus, Paclitaxel, Zotarolimus, Everolimus, Biolimus, and Others), Stent Platform (Stainless-steel, Cobalt-Chromium, Platinum-Chromium, Nitinol, and Others), Generation (1st Generation, 2nd Generation, 3rd Generation, 4th Generation), Application (Coronary Artery Disease, Peripheral Artery Disease), End User (Hospitals, Ambulatory Surgical Centers, and Others), and Region 2024-2032”. The study provides a detailed analysis of the industry, including the global drug-eluting stents market share, size, share and growth forecast. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
The global drug-eluting stents market size reached US$ 8.3 Billion in 2023. Looking forward, the market is expected to reach US$ 13.7 Billion by 2032, exhibiting a growth rate (CAGR) of 5.51% during 2024-2032.
Request to Get the Sample Report: https://www.imarcgroup.com/drug-eluting-stents-market/requestsample
Factors Affecting the Growth of the Drug-Eluting Stents Industry:
- Rapid Technological Advancements and Innovations:
Ongoing research and development are driving the market forward by creating newer and more effective stents that enhance safety and efficacy. Innovations like bioresorbable stents, which dissolve after the artery heals, are reducing long-term complications and boosting market growth. Additionally, improvements in polymer coatings and drug formulations are contributing to better patient outcomes by minimizing restenosis and lowering the risk of stent thrombosis. Investments in next-generation stents, featuring advanced materials and drug-eluting mechanisms for precise drug delivery and optimal therapeutic effects, are also fueling market expansion.
- Increasing Prevalence of Cardiovascular Diseases:
The growing incidence of cardiovascular diseases (CVDs) such as coronary artery disease, heart attacks, and strokes is driving market growth. Contributing factors like sedentary lifestyles, unhealthy diets, smoking, and high stress levels are increasing the frequency of these conditions. As a result, there is a rising demand for effective treatments, such as drug-eluting stents, which are proven to reduce the recurrence of arterial blockages after angioplasty, thereby further stimulating market growth.
- Favorable Reimbursement Policies and Increased Healthcare Expenditure:
The market is also being driven by favorable reimbursement policies and increased healthcare spending. Governments and healthcare payers are increasingly recognizing the long-term benefits of drug-eluting stents (DES), leading to more supportive reimbursement frameworks. Expanded coverage of DES under public and private insurance plans is reducing the financial burden on patients and encouraging broader adoption. Additionally, substantial healthcare budgets allocated for the treatment and management of cardiovascular diseases are facilitating the acquisition and use of advanced medical devices, further promoting market growth.
Speak to An Analyst: https://www.imarcgroup.com/request?type=report&id=4815&flag=C
Drug-Eluting Stents Market Report Segmentation:
By Coating:
- Polymer Based Coating
- Polymer Free Coating
The polymer-free coating segment leads the market due to its ability to minimize the risk of long-term complications related to polymer degradation and inflammatory responses.
By Drug:
- Sirolimus
- Paclitaxel
- Zotarolimus
- Everolimus
- Biolimus
- Others
The market is segmented by drug type, including sirolimus, paclitaxel, zotarolimus, everolimus, biolimus, and others.
By Stent Platform:
- Stainless-steel
- Cobalt-Chromium
- Platinum-Chromium
- Nitinol
- Others
Cobalt-chromium stents dominate the market segment because of their exceptional strength, flexibility, and biocompatibility, which improve stent performance and patient outcomes.
By Generation:
- 1st Generation
- 2nd Generation
- 3rd Generation
- 4th Generation
The market is categorized by generation into 1st, 2nd, 3rd, and 4th generations.
By Application:
- Coronary Artery Disease
- Peripheral Artery Disease
Coronary artery disease holds the largest market share, as it is the most common cardiovascular condition requiring stent interventions to restore blood flow and prevent heart attacks.
By End User:
- Hospitals
- Ambulatory Surgical Centers
- Others
Hospitals represent the largest market segment due to their role in performing the majority of percutaneous coronary interventions and their capability to provide advanced cardiac care.
Regional Insights:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
North America leads the drug-eluting stents market, driven by its advanced healthcare infrastructure, high prevalence of cardiovascular diseases, and substantial investment in medical research and technology.
Global Drug-Eluting Stents Market Trends:
The market is expected to grow with the rise of personalized medicine, which is fostering the development of custom stents tailored to individual patient needs. Expanding applications of drug-eluting stents in peripheral artery disease, neurovascular conditions, and non-vascular areas such as urethral and biliary strictures are also contributing to a positive market outlook. Additionally, the increasing adoption of minimally invasive techniques and robotic-assisted interventions, which enhance precision and success rates of stent placements, is further driving market growth.
Top Companies Operated in Drug-Eluting Stents Industry:
- Abbott Laboratories
- B. Braun Melsungen AG
- Biosensors International Group Ltd.
- Biotronik
- Boston Scientific Corporation
- Cardinal Health Inc.
- Cook Medical LLC (Cook Group Incorporated)
- Lepu Medical Technology (Beijing) Co. Ltd.
- Medtronic plc
- MicroPort Scientific Corporation
- Sino Medical Sciences Technology Inc.
- Terumo Corporation.
Key Highlights of the Report:
- Market Performance (2018-2023)
- Market Outlook (2024-2032)
- Market Trends
- Market Drivers and Success Factors
- Impact of COVID-19
- Value Chain Analysis
- Comprehensive mapping of the competitive landscape
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
